Drug intelligence / Profile preview

TOXAVIT

Development stage: Unknown
Lead developer: lege artis Pharma
Modality: Small Molecules
Administration: Topical, Dental

Overview

TOXAVIT is a paraformaldehyde-based dental preparation used for the devitalization of dental pulp during endodontic or root canal treatments. Developed by lege artis Pharma, it serves as an arsenic-free alternative for emergency pain management when conventional anesthesia is ineffective or vital extirpation is not possible. The formulation contains paraformaldehyde, which releases formaldehyde to devitalize the pulp tissue, combined with lidocaine hydrochloride and eugenol to provide immediate local anesthesia and pain relief. Metacresol is included for its antiseptic properties. The product is a dark grey, viscous paste designed for topical application directly into the exposed pulp cavity.

Brand names: TOXAVIT

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on TOXAVIT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOXAVIT.

Explore the full profile